I n this issue of Critical Care Medicine, Zhang and Xu (1) present a comprehensive and well-conducted systematic review and meta-analysis of the prognostic potential of lactate clearance (LC) to predict survivors and nonsurvivors among patients with critical illness. The results confirm in aggregate what each of the smaller studies suggest-that failure of lactate to decrease or clear is associated with a worse prognosis and higher mortality rate. An examination of the Forest plot ( Fig. 2 in [1] ) clearly shows that all included studies, whether among patients with sepsis or nonsepsis and taking place in either the emergency department or ICU, have relative risk reduction (RR) and 95% CIs that do not cross 1. This demonstrates a better prognosis associated with LC. Thus, the only real question is "how much"-how much of a RR is there, how much LC is superior, and how much should we try to drive LC?
How much of a RR is there? Compared with failure of LC (variably defined in each of the studies), LC is associated with a relative RR of 0.34 (95% CI, 0.34-0.53) in nonsepsis patients compared with a slightly different RR of 0.41 (95% CI, 0.28-0.60) in patients with sepsis. The study by Jansen et al (2) was analyzed in the nonsepsis group, despite the fact that 40% of this study represented patients with sepsis. Surprisingly, the authors conclude that "LC … is of limited value in patients with sepsis or septic shock." However, given the data presented, we strongly disagree with this conclusion. Their data actually support the prognostic value of LC in any of these clinical scenarios.
How much LC is superior? Two critical questions remain for clinicians: 1) What degree of LC is superior? and 2) in what time frame should that superior LC target be achieved? Unfortunately, this study adds little to this discussion as authors do not provide a summary analysis comparing the prognostic ability of various levels of LC nor any additional analyses on clearance time frames or rates of clearance. Although the Surviving Sepsis Campaign recommends lactate normalization as a target of sepsis resuscitation, this recommendation was based primarily on the lack of consensus between two randomized clinical trials that studied the use of LC as a resuscitation variable, in combination with the prevailing wisdom that "normal" is better than "abnormal." Given this lack of consensus, however, LC as a resuscitation target received relatively weak 2C recommendation. Since these guidelines were published, the study by Puskarich et al (3) has suggested that lactate normalization does indeed provide the best predictor of survival compared with any other degree of relative LC, although the observational design of the study does not answer the question of whether targeting lactate normalization improves patient outcomes.
How much should we try to drive LC? Two randomized clinical trials demonstrate that targeting modest (10-20%) LC is associated with noninferior or even superior outcomes in critically ill patients (2, 4) . Combined with the current meta-analysis, the evidence is clear that LC is a useful noninvasive resuscitation target that should be strongly considered when evaluating critically ill patients, no matter the etiology of their illness. It remains unproven if more aggressive targeting lactate normalization should indeed be our goal. If lactate results predominantly from ischemia, then rapid reversal of tissue hypoperfusion and normalization of lactate are highly likely to improve outcomes, although this hypothesis remains untested formally. However, if a significant proportion of lactate results from nonischemic mechanisms (such as increased glycolysis or mitochondrial dysfunction, as may be the case in certain patients with sepsis), attempting to drive lactate levels down under the assumption lactate is generated solely due to impaired oxygen delivery may have unintended consequences. Specifically, if one attempts to artificially drive LC through the use of extremely high volume resuscitation or aggressive use of packed RBC transfusions, patient outcomes may actually be worsened. To further assess this question, clinical trials explicitly targeting lactate normalization will be necessary to accurately assess the riskto-benefit ratio of this therapeutic target. In the meantime, the observations presented by Zhang and Xu (1) support the continually emerging evidence that clearing lactate is good
